Deferasirox Aurovitas 90 mg film-coated tablets EFG

Patient Information Leaflet

Introduction

Patient Information Leaflet

Deferasirox Aurovitas 90 mg film-coated tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.

• If you have any questions, ask your doctor or pharmacist.

• This medicine has been prescribed for you or your child only, and you must not give it to other people, even if they have the same symptoms as you. It may harm them.

  • If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet Contents

1. What Deferasirox Aurovitas is and what it is used for
2. What you need to know before taking Deferasirox Aurovitas
3. How to take Deferasirox Aurovitas
4. Possible side effects
5. How to store Deferasirox Aurovitas
6. Contents of the pack and other information

1. What Deferasirox Aurovitas is and what it is used for

What Deferasirox Aurovitas is

This medicine contains an active substance called deferasirox. It is an iron chelator, which is a medicine used to remove excess iron from the body (also known as iron overload). It binds and removes excess iron, which is then excreted mainly in the faeces.

What Deferasirox Aurovitas is used for

Repeated blood transfusions may be necessary in patients with various types of anaemia (e.g. thalassaemia, sickle cell anaemia or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can lead to an accumulation of excess iron. This is because blood contains iron, and the body has no natural way of eliminating the excess iron obtained through blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, primarily due to increased absorption of dietary iron in response to low blood cell counts. Over time, excess iron can damage important organs such as the liver and heart. Medicines known as iron chelators are used to remove excess iron and reduce the risk of organ damage.

Deferasirox is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.

Deferasirox is also used to treat chronic iron overload when treatment with deferoxamine is contraindicated or not suitable in patients with beta thalassaemia major who have iron overload due to infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.

Deferasirox is also used to treat patients aged 10 years and older who have iron overload associated with thalassaemia syndromes but who are not transfusion-dependent, when treatment with deferoxamine is contraindicated or not suitable.

2. What you need to know before taking Deferasirox Aurovitas

Do not take Deferasirox Aurovitas

• If you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6). If this applies to you, inform your doctor before taking deferasirox. If you think you may be allergic, consult your doctor.
• If you have moderate or severe kidney disease.
• If you are currently taking any other iron-chelating medicine.

Deferasirox Aurovitas is not recommended

• If you have advanced myelodysplastic syndrome (MDS, reduced production of blood cells by the bone marrow) or advanced cancer.

Warnings and precautions

Talk to your doctor or pharmacist before starting this medicine

• If you have kidney or liver problems.
• If you have heart problems due to iron overload.
• If you notice a marked decrease in the amount of urine you pass (a sign of kidney problems).
• If you develop a severe rash, or have difficulty breathing, dizziness, or swelling, mainly of the face and throat (signs of a severe allergic reaction; see also section 4 "Possible side effects").
• If you experience a combination of any of the following symptoms: rash, skin redness, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, swollen lymph nodes (signs of a severe skin reaction; see also section 4 "Possible side effects").
• If you notice a combination of drowsiness, pain in the upper right part of the abdomen, yellowing or increased yellowing of the skin or eyes, and dark-colored urine (signs of liver problems).
• If you notice difficulty thinking, remembering information, or solving problems, or if you are less alert or awake, or feel drowsy and weak (signs of high blood ammonia levels, which may be associated with liver or kidney problems; see also section 4 "Possible side effects").
• If you experience vomiting with blood and/or black stools.
• If you have frequent abdominal pain, particularly after eating or taking deferasirox.
• If you have frequent heartburn.
• If you have low platelet or white blood cell counts in your blood test.
• If you have blurred vision.
• If you have diarrhoea or vomiting.

If you are in any of these situations, inform your doctor immediately.

Monitoring your treatment with Deferasirox Aurovitas

During treatment, you will have regular blood and urine tests. These tests will monitor the amount of iron in your body (serum ferritin level) to assess how well deferasirox treatment is working. The tests will also monitor kidney function (blood creatinine level, presence of protein in urine) and liver function (blood transaminase levels). Your doctor may recommend a kidney biopsy if significant kidney damage is suspected. Magnetic resonance imaging (MRI) tests may also be performed to determine the amount of iron in your liver. Your doctor will use these test results to determine the most appropriate deferasirox dose for you and to decide when to stop treatment.

Your vision and hearing will be checked annually during treatment as a precautionary measure.

Other medicines and Deferasirox Aurovitas

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. This includes in particular:

• Other iron chelators – these must not be taken with deferasirox.
• Antacids (medicines used to treat heartburn) containing aluminium – these must not be taken at the same time of day as deferasirox.
• Cyclosporine (used to prevent organ transplant rejection or for other conditions such as rheumatoid arthritis or atopic dermatitis).
• Simvastatin (used to lower cholesterol levels).
• Certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids).
• Oral bisphosphonates (used to treat osteoporosis).
• Anticoagulant medicines (used to prevent or treat blood clots).
• Hormonal contraceptives (medicines for birth control).
• Bepridil, ergotamine (used for heart conditions and migraines).
• Repaglinide (used to treat diabetes).
• Rifampicin (used to treat tuberculosis).
• Phenytoin, phenobarbital, carbamazepine (used to treat epilepsy).
• Ritonavir (used to treat HIV infection).
• Paclitaxel (used to treat cancer).
• Theophylline (used to treat respiratory diseases such as asthma).
• Clozapine (used to treat psychiatric disorders such as schizophrenia).
• Tizanidine (used as a muscle relaxant).
• Cholestyramine (used to reduce blood cholesterol levels).
• Busulfan (used as pre-transplant treatment to destroy the original bone marrow before transplantation).
• Midazolam (used to relieve anxiety and/or sleep problems).

Additional tests may be needed to monitor blood levels of some of these medicines.

Elderly (aged 65 years and older)

Deferasirox can be used in people over 65 years of age at the same dose as in other adults. Elderly patients may experience more side effects (especially diarrhoea) than younger patients. Your doctor should closely monitor any side effects that may require dose adjustment.

Children and adolescents

Deferasirox can be used in children and adolescents aged 2 years and older who receive regular blood transfusions, and in children and adolescents aged 10 years and older who do not receive regular blood transfusions. As the patient grows, the doctor will adjust the dose accordingly.

Deferasirox is not recommended in children under 2 years of age.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medicine.

Treatment with deferasirox is not recommended during pregnancy unless clearly necessary.

If you are currently using a hormonal contraceptive to prevent pregnancy, you should use an additional or different contraceptive method (e.g. condom), as deferasirox may reduce the effectiveness of hormonal contraceptives.

Breastfeeding is not recommended during treatment with deferasirox.

Driving and using machines

If you feel dizzy after taking deferasirox, do not drive or operate tools or machinery until you feel well again.

3. How to take Deferasirox Aurovitas

Treatment with deferasirox will be supervised by a doctor experienced in the treatment of iron overload caused by blood transfusions.

Follow exactly the instructions for use of this medicine given by your doctor. If in doubt, consult your doctor or pharmacist again.

How much Deferasirox Aurovitas you should take

The dose of deferasirox is based on body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.

• The usual daily dose of deferasirox film-coated tablets at the start of treatment for patients receiving periodic blood transfusions is 14 mg per kilogram of body weight. Your doctor may recommend a higher or lower dose depending on your individual treatment needs.
• The usual daily dose of deferasirox film-coated tablets at the start of treatment for patients not receiving periodic blood transfusions is 7 mg per kilogram of body weight.
• Depending on how you respond to treatment, your doctor may later adjust your dose to a higher or lower level.
• The maximum recommended daily dose of deferasirox film-coated tablets is:
• 28 mg per kilogram of body weight for patients receiving periodic blood transfusions,
• 14 mg per kilogram of body weight for adults not receiving periodic blood transfusions,
• 7 mg per kilogram of body weight for children and adolescents not receiving periodic blood transfusions.

Deferasirox Aurovitas is not available in dispersible tablets. To use dispersible tablets, other medications containing deferasirox must be used. If switching from these dispersible tablets to deferasirox film-coated tablets, your dose will change. Your doctor will calculate the dose you need and tell you how many film-coated tablets to take each day.

When to take Deferasirox Aurovitas

• Take deferasirox once daily, every day, at the same time, with a glass of water.
• Take deferasirox film-coated tablets on an empty stomach or with light meals.

Taking deferasirox at the same time each day will also help you remember when to take your tablets.

Patients who have difficulty swallowing tablets may crush deferasirox film-coated tablets and take the powder mixed with soft food such as yoghurt or apple puree (applesauce). The entire dose should be consumed immediately, without saving any for later.

How long to take Deferasirox Aurovitas

Continue taking deferasirox every day for as long as your doctor instructs you. This is a long-term treatment, which may last for months or years. Your doctor will monitor your condition periodically to ensure the treatment is having the desired effect (see also section 2: "Monitoring your treatment with Deferasirox Aurovitas").

If you have any doubts about how long you should take deferasirox, consult your doctor.

If you take more Deferasirox Aurovitas than you should

If you have taken too much deferasirox, or if someone else accidentally takes your tablets, contact your doctor or go to a hospital immediately. Show the doctor the tablet packaging. You may require urgent medical treatment. You may experience effects such as abdominal pain, diarrhoea, nausea and vomiting, and kidney or liver problems, which could be serious. You may also contact your pharmacist immediately or call the Toxicology Information Service at 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take Deferasirox Aurovitas

If you forget to take a dose, take it as soon as you remember on the same day. Take your next dose according to your usual schedule. Do not take a double dose the next day to make up for the missed dose(s).

If you stop taking Deferasirox Aurovitas

Do not stop your treatment with deferasirox unless your doctor tells you to. If you stop taking it, excess iron will not be removed from your body (see also previous section "How long to take Deferasirox Aurovitas").

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them. Most adverse effects are mild or moderate and usually go away after a few days or weeks of treatment.

Some adverse effects may be serious and require immediate medical attention.

These adverse effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1000 people)

• If you develop a severe rash, or have difficulty breathing and dizziness or swelling, especially of the face and throat (signs of a severe allergic reaction).
• If you experience a combination of any of the following symptoms: rash, skin redness, blisters on lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, swollen lymph nodes (signs of a severe skin reaction).
• If you notice a marked decrease in urine volume (a sign of kidney problems).
• If you notice a combination of drowsiness, pain in the upper right part of the abdomen, yellowing or increased yellowing of the skin or eyes, and dark-colored urine (signs of liver problems).
• If you experience difficulty thinking, remembering information, or solving problems, or are less alert or awake, or feel drowsy and weak (signs of high blood ammonia levels, which may be associated with liver or kidney problems and may lead to changes in brain function).
• If you have vomiting with blood and/or black stools.
• If you have frequent abdominal pain, particularly after eating or taking deferasirox.
• If you have frequent heartburn.
• If you have partial loss of vision.
• If you have severe pain in the upper part of the stomach (pancreatitis).

Stop taking the medicine and contact your doctor immediately.

Some adverse effects may become serious.

These adverse effects are uncommon

• If you have blurred vision.
• If you experience hearing loss.

Inform your doctor as soon as possible.

Other adverse effects

Very common (may affect more than 1 in 10 people)

• Abnormalities in kidney function tests.

Common (may affect up to 1 in 10 people)

• Gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal pain, bloating, constipation, indigestion.
• Rash.
• Headache.
• Abnormalities in liver function tests.
• Itching.
• Abnormalities in urine tests (protein in urine).

If you experience any of these effects severely, inform your doctor.

Uncommon (may affect up to 1 in 100 people)

• Dizziness.
• Fever.
• Sore throat.
• Swelling in arms and legs.
• Changes in skin color.
• Anxiety.
• Sleep disturbances.
• Fatigue.

If you experience any of these effects severely, inform your doctor.

Frequency not known (cannot be estimated from available data)

• Decrease in the number of blood cells involved in blood clotting (thrombocytopenia), decrease in red blood cells (worsening of anemia), decrease in white blood cells (neutropenia), or decrease in all types of blood cells (pancytopenia).
• Hair loss.
• Kidney stones.
• Low urine output.
• Rupture of the stomach or intestinal wall, which may be painful and cause nausea.
• Severe pain in the upper part of the stomach (pancreatitis).
• Abnormal levels of acid in the blood.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicinal Products: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Deferasirox Aurovitas

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging and blister after EXP. The expiry date is the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE point at your pharmacy. Ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Deferasirox Aurovitas

• The active substance is deferasirox.

• Each film-coated tablet contains 90 mg of deferasirox.

• The other components are:

Core: microcrystalline cellulose (Grade 101 and 102), crospovidone (type A), poloxamer (type 188), povidone (K 30), colloidal anhydrous silica, and magnesium stearate.

Coating of the tablet: hypromellose 2910 (6 mPas), titanium dioxide, macrogol 6000, talc, indigo carmine aluminium lake (3% - 5%), and aluminium indigo carmine lacquer (11% - 14%).

Appearance of the product and contents of the pack

Film-coated tablet.

Deferasirox Aurovitas 90 mg film-coated tablets EFG

Film-coated tablet, light blue, oval, biconvex, with bevelled edges, engraved with "DF" on one side and "90" on the other.

Deferasirox Aurovitas film-coated tablets EFG are available in transparent PVC/PVDC/Aluminium blisters and transparent PVC/Aluminium blisters containing 30, 90 and 300 film-coated tablets.

Only some pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid,

Spain

Manufacturer:

APL Swift Services (Malta) Ltd,

HF26, Hal Far Industrial Estate, Hal Far

Birzebbugia, BBG 3000,

Malta

Or

Generis Farmacêutica S.A., Portugal

Rua de João de Deus, nº 19, Venda Nova,

2700 487, Amadora

Portugal

Or

Arrow Generiques

26 Avenue Tony Garnier,

69007, Lyon,

France

This medicinal product is authorised in the Member States of the European Economic Area under the following names:

Germany: DeferasiPUREN 90 mg Filmtabletten

Belgium: Deferasirox AB 90 mg filmomhulde tabletten / comprimés pelliculés / Filmtabletten

Spain: Deferasirox Aurovitas 90 mg film-coated tablets EFG

France: DEFERASIROX ARROW 90 mg, comprimé pelliculé

Italy: Deferasirox Aurobindo

Netherlands: Deferasirox Aurobindo 90 mg filmomhulde tabletten

Portugal: Deferasirox Generis

Date of the most recent review of this leaflet: November 2025

Detailed information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).